July 23, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Dainippon Sumitomo, AstraZeneca to Develop Antiallergic Drug
 

 Antiallergic Drug
Osaka, May 8, 2008 (Jiji Press) - Dainippon Sumitomo Pharma Co. <4506> said Thursday it will start clinical development of a therapeutic agent for allergic disorders in collaboration with AstraZeneca PLC.

Through joint researches since 2004, the Japanese and British companies have discovered a chemical compound which can act as an immune response modifier that is effective against bronchial asthma and allergic rhinitis.

If the drug is successfully developed, Dainippon Sumitomo will sell the product in Japan, China, South Korea and Taiwan, while AstraZeneca will cover the rest of the world.

Dainippon Sumitomo will receive royalties for sales in the United States and some European countries.

The market for bronchial asthma drugs is estimated at 200 billion yen for Japan and 2 trillion yen for the world. The market for allergic rhinitis drugs is seen at 100 billion yen for Japan and 1.6 trillion yen for the world.

By Jiji Press, (c) Jiji Press

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Dainippon Sumitomo News  
  Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S.  (Oct 10, 2013)
  Dainippon Sumitomo Pharma Opens Subsidiary in Singapore  (Jan 22, 2013)
  Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent  (Dec 28, 2012)
  NOTICE of establishment of Drug Discovery Consortium in neuropsychiatric area  (Oct 23, 2008)
  Dainippon Sumitomo, AstraZeneca to Develop Antiallergic Drug  (May 8, 2008)
  Dainippon Sumitomo Pharma Review of Overseas Development of Lurasidone (SM-13496), an Atypical Antipsychotic  (Dec 13, 2006)
  Dainippon Sumitomo Pharma Revises Domestic Development Plan of AC-5216, an Antianxiety/antidepressant Agent  (Nov 28, 2006)
  Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'  (Sept 21, 2006)
  Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'  (Sept 21, 2006)
  Dainippon Sumitomo Pharma Enters into Partnership Agreement on Anti-Hypertension and Hepatocellular Cancer Drugs  (July 26, 2006)



 Recent  Drugs & OTC News   
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)
Dainippon Screen Launches High-speed Three-dimensional Cell Culture Scanner (Aug 8, 2013)
Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria (Aug 1, 2013)

More Drugs & OTC news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)